PY 12/19/24 PY 12/19/24 Season’s Greetings from the Ab Initio Pharma Team Read More PY 12/6/24 PY 12/6/24 Did You Know Ab Initio Leads the Way in Developing Inhaled and Nasal Biologics?: Meet with our CSO, YY at DDL 2024 Read More PY 12/1/24 PY 12/1/24 Join Ab Initio Pharma at DDL 2024: Shaping the Future of Inhaled Therapies Read More PY 11/27/24 PY 11/27/24 Ab Initio Featured on BioBeacon Read More PY 11/24/24 PY 11/24/24 Ab Initio Pharma Innovates at BioTech in NSW: Meet Our Team on December 6th in Sydney Read More PY 10/31/24 PY 10/31/24 Ab Initio Pharma Celebrates the Success of the Inaugural NSW Drug Discovery Conference Read More PY 10/11/24 PY 10/11/24 Book a time to meet with the team at AusBio 2024 Read More PY 10/1/24 PY 10/1/24 Ab Initio attending AusBiotech 2024 Read More PY 9/27/24 PY 9/27/24 "Beware the Wolf in Sheep's Clothing: Many Companies Claim GMP Compliance Without Holding a License—Verify that Your CDMO and Formulation Provider has a suitable GMP licence on the TGA Website" Read More PY 9/25/24 PY 9/25/24 Discover Ab Initio's Mission: Driving Innovation in Therapeutics – An Exclusive Interview at ARCS Australia 2024 Read More PY 9/18/24 PY 9/18/24 Ab Initio Joins Groundbreaking Project to Develop World’s First Multi-Organ Radiation Protectant Read More PY 9/15/24 PY 9/15/24 Ab Initio Pharma Partners on Grant for Personalised Aerosol Therapy System for next-generation biological therapeutics Read More PY 9/9/24 PY 9/9/24 Did You Know Ab Initio formulates and manufactures complex semisolids to GMP? Read More PY 9/3/24 PY 9/3/24 Join US at the “Future of Inhalation Drug Delivery” Conference in Parma to learn about non-clinical tests for inhalation product evaluation Read More PY 8/31/24 PY 8/31/24 Join us at the Future of Inhalation Drug Delivery Conference to learn about next-gen MDI development Read More PY 8/29/24 PY 8/29/24 Ab Initio Pharma Announces Sponsorship of the 2024 NSW Drug Discovery Forum Commercialisation Award Read More PY 8/28/24 PY 8/28/24 Advanced Techniques in pMDI Characterisation: Insights from Ab Initio and OzUK Read More PY 8/13/24 PY 8/13/24 Ab Initio Pharma Team Shines at Sydney City to Surf Event Read More PY 6/21/24 PY 6/21/24 Learn about Inhaled Biologics at SMI London Conference Read More PY 6/11/24 PY 6/11/24 Join us at ARCS 2024 Read More Older Posts
PY 12/6/24 PY 12/6/24 Did You Know Ab Initio Leads the Way in Developing Inhaled and Nasal Biologics?: Meet with our CSO, YY at DDL 2024 Read More
PY 12/1/24 PY 12/1/24 Join Ab Initio Pharma at DDL 2024: Shaping the Future of Inhaled Therapies Read More
PY 11/24/24 PY 11/24/24 Ab Initio Pharma Innovates at BioTech in NSW: Meet Our Team on December 6th in Sydney Read More
PY 10/31/24 PY 10/31/24 Ab Initio Pharma Celebrates the Success of the Inaugural NSW Drug Discovery Conference Read More
PY 9/27/24 PY 9/27/24 "Beware the Wolf in Sheep's Clothing: Many Companies Claim GMP Compliance Without Holding a License—Verify that Your CDMO and Formulation Provider has a suitable GMP licence on the TGA Website" Read More
PY 9/25/24 PY 9/25/24 Discover Ab Initio's Mission: Driving Innovation in Therapeutics – An Exclusive Interview at ARCS Australia 2024 Read More
PY 9/18/24 PY 9/18/24 Ab Initio Joins Groundbreaking Project to Develop World’s First Multi-Organ Radiation Protectant Read More
PY 9/15/24 PY 9/15/24 Ab Initio Pharma Partners on Grant for Personalised Aerosol Therapy System for next-generation biological therapeutics Read More
PY 9/9/24 PY 9/9/24 Did You Know Ab Initio formulates and manufactures complex semisolids to GMP? Read More
PY 9/3/24 PY 9/3/24 Join US at the “Future of Inhalation Drug Delivery” Conference in Parma to learn about non-clinical tests for inhalation product evaluation Read More
PY 8/31/24 PY 8/31/24 Join us at the Future of Inhalation Drug Delivery Conference to learn about next-gen MDI development Read More
PY 8/29/24 PY 8/29/24 Ab Initio Pharma Announces Sponsorship of the 2024 NSW Drug Discovery Forum Commercialisation Award Read More
PY 8/28/24 PY 8/28/24 Advanced Techniques in pMDI Characterisation: Insights from Ab Initio and OzUK Read More
